Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646602 | 0.90 | AAK1 (0.52) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL4822133 | 0.89 | AAK1 (0.59) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL15882115 | 0.88 | AAK1 (0.48) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL30931999 | 0.88 | AAK1 (0.50) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL21626169 | 0.87 | HIF1A (0.46) | AAK1HIF1ADGAT1SMN1; SMN2CA1 | |
| SCHEMBL65795 | 0.86 | AAK1 (0.49) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL3763011 | 0.86 | AAK1 (0.49) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL16156534 | 0.86 | PRMT5 (0.50) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL15184583 | 0.85 | AAK1 (0.51) | AAK1PRMT5WDR77HIF1ABACE1 | |
| SCHEMBL65967 | 0.85 | AAK1 (0.51) | AAK1PRMT5WDR77HIF1ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548867-B2 | Amido compounds as AhR modulators | IDEA YA BIOSCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | IDEAYA BIOSCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| US-9833440-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170157096-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. | 2017-06-08 | — | — | US | disclosed |
| EP-2807172-B1 | PYRIMIDOOXAZOCINE DERIVATIVES AS MTOR-INHIBITORS | SANOFI SA (FR) | 2016-11-30 | — | — | EP | disclosed |
| US-9120812-B2 | Pyrimidooxazocine derivatives as mTOR-inhibitors | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20100062937-A1 | BENZANILIDES WITH INSECTICIDAL ACTIVITY | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | ADAMS JERRY LEROY | 2009-01-29 | — | — | US | disclosed |
| EP-1432714-B1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | ADAMS JERRY | 2007-12-20 | — | — | US | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| US-7217710-B2 | Substituted pyrazolopyrimidines | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1432714-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1432714-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003029209-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062937-A1 | BENZANILIDES WITH INSECTICIDAL ACTIVITY | CBR3, HCN3, HAX1 | AAK1 4079/4885PRMT5 3390/4885WDR77 3392/4885 |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | AHR, MCL1, ARNT | AAK1 2317/4885PRMT5 756/4885WDR77 2973/4885 |
| US-20170157096-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | AAK1 2110/4885PRMT5 2673/4885WDR77 4257/4885 |
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | DPYD, TPMT, TYMP | AAK1 3054/4885PRMT5 1015/4885WDR77 2840/4885 |
| US-11548867-B2 | Amido compounds as AhR modulators | AHR, ARNT, RXRB | AAK1 2874/4885PRMT5 329/4885WDR77 2621/4885 |
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | DPYD, TPMT, TYMP | AAK1 3054/4885PRMT5 1015/4885WDR77 2840/4885 |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | DPYD, TYMP, TYMS | AAK1 1812/4885PRMT5 1355/4885WDR77 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.